Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Gilead Sciences Inc (NASDAQ:GILD) recently filed its 10-Q report ... This growth is largely due to higher demand and average ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...

Gilead Sciences, Inc. (NASDAQ:GILD ... third quarter pricing dynamics discussed earlier that are not expected to repeat. Turning to Slide 10, Biktarvy third quarter sales of $3.5 billion increased 13% ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...